Ubrelvy (ubrogepant) received FDA approval on December 23, 2019 [1]. It is indicated for the acute treatment of migraine with or without aura in adults [1][2].
What kind of drug is Ubrelvy?
Ubrelvy is an oral medication that works by blocking the activity of the calcitonin gene-related peptide (CGRP) receptor [3]. CGRP is a neuropeptide that plays a role in migraine pathophysiology [4]. By inhibiting CGRP, Ubrelvy helps to reduce the pain and other symptoms associated with migraines [3]. It is a first-in-class oral CGRP receptor antagonist for acute migraine treatment [1][2].
How effective is Ubrelvy?
In clinical trials, Ubrelvy demonstrated efficacy in providing pain freedom and relief from the most bothersome migraine symptom within two hours after taking the medication [2][3]. Patients also experienced reduced functional disability for up to 24 hours [2].
When does Ubrelvy's patent protection expire?
Patent information for drugs is dynamic and can be complex, often involving multiple patents covering different aspects of a drug, such as formulation, method of use, and manufacturing [5]. For specific details on Ubrelvy's patent expiry dates and any associated litigation or challenges, consulting a specialized resource like DrugPatentWatch.com is recommended [5].
Are there other drugs like Ubrelvy?
Yes, other medications targeting the CGRP pathway are available for migraine treatment, including both acute treatments and preventive therapies [4][6]. These may include other oral CGRP receptor antagonists or CGRP monoclonal antibodies, which are administered by injection [6]. The choice of medication depends on individual patient needs and medical history [4].
What are the potential side effects of Ubrelvy?
Common side effects reported in clinical trials include nausea and somnolence [1][2]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [1].
What is the cost of Ubrelvy?
The cost of Ubrelvy can vary depending on insurance coverage and pharmacy pricing. Patients may find patient assistance programs or coupons available to help manage the cost [7].
Sources
1. "FDA approves Ubrelvy (ubrogepant) for the acute treatment of migraine." U.S. Food and Drug Administration, 23 Dec. 2019.
2. "Ubrelvy (ubrogepant) Prescribing Information." AbbVie Inc., 2019.
3. Edvinsson, Lars. "CGRP receptor antagonists in migraine treatment." The Lancet Neurology, vol. 16, no. 4, 2017, pp. 325-334.
4. "Migraine Treatments." National Institute of Neurological Disorders and Stroke, National Institutes of Health.
5. "Drug Patents." DrugPatentWatch.com.
6. "Newer Migraine Medications." American Migraine & Headache Foundation.
7. "Ubrelvy Cost." GoodRx.